Skip to content
naulon
Not checkedNot checked for notices yet.

Impact of Antithrombin Activity Levels Following Recombinant Antithrombin Gamma Therapy in Patients with Sepsis-Induced Disseminated Intravascular Coagulation

Tomohiko Akahoshi MD, PhD, Noriyuki Kaku MD, PhD, Yuji Shono MD, PhD and 8 more

Clinical and Applied Thrombosis/Hemostasis · 2022

doi:10.1177/10760296221135790 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Recombinant antithrombin gamma (rAT) is reported as an effective drug for patients with disseminated intravascular coagulation (DIC) in Japan. As the appropriate dose and targeted AT activity remain unknown, this study aimed to determine these aspects for sepsis-induced DIC. Thirty-one patients with septic shock and DIC with AT levels <70% were treated with rAT between May 2018 and December 2020. The recovery rates from DIC were 32.2% and 63.3% on day 3 and 5 post administration, respectively. Recovery and survival rates were significantly higher in patients who achieved AT activity ≥70% or 80% on day 3 post administration. Receiver operating characteristic curve analysis revealed that the cutoff values of post-treatment AT activity on day 3 for 28-day survival and 5-day recovery from DIC were 79.5% and 81.5%, respectively. Patients who did not achieve AT activity ≥80% on day 3 presented a lower base level of AT activity and lower dose supplementation. Our results suggest that targeted AT activity should be at least 70%, and ideally 80%, and sufficient doses to maintain this activity are required to achieve better outcomes.

Abstract licence: CC BY-NC

References18

    18 more references, whose wording the paper’s licence keeps private.

    Reads

    Read by people on this page

    None yet.

    Checked or read by AI through naulon

    None yet.

    A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

    Are you an author?

    Is this your paper?

    Claim it to add your note and be paid when agents cite it. Free.